Figure 2

Selective in-vitro cell killing of human cancer cells by exposure to linear N'-capped PRGPRP-amide and the derived cyclic amphiphilic analogue, THR53. (cyc-[FPPRGPRPVKLALKLALK]) A Photomicrographs illustrating typical in-vitro morphological appearances of RT112 human bladder cancer cells (Left hand panels) and normal human fibroblasts (Right hand panels) following exposure to 5.0 mM PRGPRP (Ac-Pro-Arg-Gly-Pro-Arg-Pro-NH₂) or control nonsense peptide. PRGPRP causes complete necrosis of RT112 bladder cancer cells but increases the confluent cell density of normal diploid fibroblasts (Magnification ×40). B. Photomicrographs illustrating typical in-vitro morphological appearances of NCI-H460 human non-small cell lung cancer cells (Left hand panels) and normal diploid human keratinocytes (Right hand panels) following exposure to 200 μM THR53 or control nonsense peptide. (Magnification × 40) C. Macroscopic appearances of clonogenic assay tissue culture wells of RT112 human bladder cancer cells exposed to 5 mM PRGPRP (left hand panels) and H460 human non-small cell lung cancer cells exposed to 200 μM THR53 (right hand panels).